{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    33,
    44,
    45,
    46,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6",
        "affectedSection": "Section 6.1, 6.4.1.1, 6.10",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified the descriptive and optional nature of subsequent overall survival (OS) analyses after statistical significance is reached."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6",
        "affectedSection": "Section 5.1.1, Appendix 8",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added Severe Cutaneous Adverse Reactions (SCARs) as a risk and safety precaution for atezolizumab."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_6",
        "affectedSection": "Appendix 12",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated management guidelines for Grade 3 dermatologic events and added guidelines for SJS/TEN."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_6",
        "affectedSection": "Section 1.6.3, 5.1, Appendix 12",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduction of COVID-19 risk considerations, exclusion criteria, and management guidelines."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_6",
        "affectedSection": "Section 4.1.2",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Broadened exclusion criteria for severe infections to include investigator discretion on patient safety."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6",
        "reasonText": "Align with updates in the Atezolizumab Investigatorâ€™s Brochure, Version 17.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_6",
        "reasonText": "Address risks and operational considerations related to the COVID-19 pandemic.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_6",
        "reasonText": "Improve clarity and consistency across the protocol document.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.6.3",
        "afterText": "COVID-19 Considerations",
        "summary": "New section added to describe COVID-19-related risks."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1.2",
        "beforeText": "Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia",
        "afterText": "Severe infection within 4 weeks prior to initiation of study treatment... updated to include any active infection that, the opinion of the investigator, could impact patient safety",
        "summary": "Expanded exclusion criteria for infections based on investigator opinion."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1.1",
        "afterText": "Severe Cutaneous Adverse Reactions (SCARs)",
        "summary": "Added SCARs as a specific risk associated with atezolizumab."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Appendix 12",
        "beforeText": "Management Guidelines for Hepatic Events",
        "afterText": "Management Guidelines for Hepatic Events for Patients with Hepatocellular Carcinoma",
        "summary": "Updated hepatic event management to align with Investigator's Brochure v17."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_6",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1",
        "beforeText": "Overall survival (OS) analyses",
        "afterText": "Descriptive and optional nature of subsequent OS analyses once statistical significance is reached",
        "summary": "Clarified the status of OS analyses post-statistical significance."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 3,
      "changeCount": 5
    }
  }
}